Biogen boosts investment in neurology with $1 billion Ionis deal
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Ionis Pharmaceuticals (IONS) PT Raised to $75 at BMO Capital on Expanded Biogen Deal
April 20, 2018 9:51 AM EDTBMO Capital raised its price target on Ionis Pharmaceuticals (NASDAQ: IONS) to $75.00 (from $70.00) while maintaining a Outperform rating.
Analyst Do Kim commented, "We are raising our target price to $75 from $70, as an expanded collaboration with Biogen brings in $1bn cash, consisting of an... More
